Research Article

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Bader Alshamsan,1,2 Ahmed Mostafa Gad,1,3 Maaz Kamal Alata,1,4 Mashari Alzahrani,1 Tusneem Elhassan,1 and Jean Paul Atallah1

1Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
2Department of Medicine, Qassim Medical College, Qassim University, Qassim, Saudi Arabia
3Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4Medical Oncology Department, Prince Mohamed Bin Naser Hospital, Gizan, Saudi Arabia

Correspondence should be addressed to Bader Alshamsan; bshmsan@qu.edu.sa

Received 1 December 2021; Revised 23 February 2022; Accepted 8 March 2022; Published 5 April 2022

Academic Editor: Goo Lee

Copyright © 2022 Bader Alshamsan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC.

Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity.

Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m² capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; P = 0.02). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS (P = 0.02), better performance status (P = 0.02), and absence of brain metastasis (P = 0.04) were associated with prolonged progression-free survival.

Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.

1. Introduction

Nasopharyngeal carcinoma (NPC) is a rare malignancy responsible for approximately 0.7% of all new cancers diagnosed worldwide in 2020 [1]. The highest NPC incidence is observed in Asia, followed by Africa, and NPC is rarely diagnosed in Europe and North America [2]. In Saudi Arabia, NPC is more common in the central and northern parts of the country (e.g., Qassim and Jouf) [3]. The non-keratinizing histological subtype is prevalent in endemic regions and is associated with Epstein–Barr virus infection, with higher sensitivity to chemotherapy and radiotherapy [4, 5].

The recommended regimen for primary definitive treatment is concurrent chemoradiotherapy plus (neo)adjuvant cisplatin-based chemotherapy [6]. Cisplatin/gemcitabine is the first-line therapy for recurrent or metastatic disease (R/M) [6–8]. Most patients with R/M NPC have already exhausted platinum-based therapy, and there is no substantial evidence to support the choice of treatment in subsequent lines [9]. Palliative combination therapy uses various effective agents that show significant treatment benefits;
however, toxicity is significantly high [10–14]. Single-agent chemotherapy, such as gemcitabine [15], paclitaxel [16], irinotecan [17], methotrexate [18], and capecitabine [19, 20], is a viable option for the management of R/M NPC. Immunotherapy also demonstrated moderate efficacy in non-randomized trials of patients with pretreated R/M NPC.[21–23]

Capecitabine monotherapy in NPC was evaluated initially in China in a phase II trial of 17 patients [19], then the same author reported the outcomes of 49 patients in a retrospective study [20]. The objective response rate (ORR) was 23.5% and 37%, respectively. Ethnic and geographical differences in the tolerability of capecitabine were observed with other solid malignancies [24]. Studies comparing capecitabine usage in Arab or Middle Eastern ethnicity are lacking. This study aimed to evaluate the efficacy and tolerability of capecitabine in patients with R/M NPC and to identify potential prognostic factors for clinical outcomes.

2. Materials and Methods

The electronic medical records of a consecutive cohort of patients who received capecitabine as a single-agent treatment for R/M NPC between April 2011 and August 2019 at the King Faisal Specialist Hospital and Research Center, Riyadh, were reviewed. Ethical approval was obtained from the Research Approval Committee (RAC# 2191100), and the requirement for patient informed consent was waived. The data obtained included patient characteristics, performance status, baseline laboratory test results, staging, pathological features, treatment lines, starting dose of capecitabine, dose modifications, best responses, toxicity profiles, and time to progression.

The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) assessment was used, and tumors were staged according to the American Joint Committee on Cancer Union for International Cancer Control Tumor–Node–Metastasis staging system.

The standard dose of capecitabine in our institution is 1,250 mg/m² twice daily for 2 weeks, followed by a 1-week rest in 3-week cycles. However, the starting dose could be 850 mg/m² or 1000 mg/m² and escalate to the standard dose if tolerated well. All patients underwent baseline staging with magnetic resonance imaging (MRI) of the head and neck, computed tomography (CT) of chest, abdomen, and pelvis, and bone scan or positron emission tomography (PET) CT scans.

The patients were assessed before the second cycle in the oncology clinic, and prechemotherapy assessment clinic for clinical evaluation and revision of laboratory work, including complete blood counts, renal and hepatic profiles, and management of treatment-related toxicity, were done if needed. Treatment-related toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (version 4.0).

The objective responses were assessed every three cycles with MRI of the head and neck, chest abdomen, and pelvis CT scan; bone scan, or PET CT where appropriate, using the Response Evaluation Criteria in Solid Tumors (version

Table 1: Patients and disease characteristics (n = 51).

| Characteristics                        | Number/median (frequency/IQR) |
|----------------------------------------|-------------------------------|
| Age at diagnosis                       | 42 (35.5–52.5)               |
| Sex                                     |                               |
| Male                                    | 39 (76.5)                     |
| Female                                  | 12 (23.5)                     |
| ECOG-PS before starting capecitabine    |                               |
| 0/1                                     | 34 (66.7)                     |
| 2                                       | 17 (33.3)                     |
| History of smoking                     |                               |
| Present                                 | 8 (15.7)                      |
| Absent                                  | 28 (54.9)                     |
| NA                                      | 15 (29.4)                     |
| Stage at initial diagnosis              |                               |
| I                                       | 0                             |
| II                                      | 1                             |
| III                                     | 5 (9.8)                       |
| IVA                                     | 21 (43.1)                     |
| IVB                                     | 24 (47.1)                     |
| Metastatic sites                        |                               |
| Lung                                    | 28 (54.9)                     |
| Liver                                   | 17 (33.3)                     |
| Bone                                    | 24 (47.1)                     |
| Brain                                   | 4 (7.8)                       |
| Recurrence sites                        |                               |
| Local only                              | 4 (7.8)                       |
| Distant                                 | 15 (29)                       |
| Both                                    | 8 (15.7)                      |
| Prior chemotherapy                      | 51 (100)                      |
| First-line:                             |                               |
| Platinum-based                         | 51 (100)                      |
| With taxane                             | 21 (41.1)                     |
| With anthracycline                      | 27 (53)                       |
| With gemcitabine                        | 3 (5.9)                       |
| Second-line:                            |                               |
| Platinum-based                         | 17 (33)                       |
| With taxane                             | 15 (29.4)                     |
| With gemcitabine                        | 2 (3.9)                       |
| Monotherapy                             | 23 (45)                       |
| Taxane                                  | 19 (37.2)                     |
| Platinum                                | 3 (5.9)                       |
| Gemcitabine                             | 1 (1.9)                       |
| Radiation therapy                       |                               |
| Concurrent chemoradiotherapy            | 47 (92)                       |
| Reirradiation                           | 20 (39.2)                     |
| Capecitabine used as                    |                               |
| First recurrence                        | 11 (21.6)                     |
| Second-line                             | 18 (35.3)                     |
| Third-line                              | 22 (43.1)                     |

Abbreviations: ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HFS: hand-foot syndrome; IQR: interquartile range.
1.1). All patients were assessed for clinical outcomes, including ORR, progression-free survival (PFS), and overall survival (OS). The date of the last follow-up was September 2021.

ORR was defined as the sum of the percentage of patients who had partial or complete responses after starting capecitabine. The disease control rate (DCR) comprised complete response, partial response, and stable disease. The duration of response to capecitabine was defined as the time from confirmation of partial response, complete response, or stable disease until disease progression or death. PFS was defined as the time from the beginning of capecitabine therapy until disease progression or death. The time from the beginning of capecitabine therapy until death from any cause was defined as OS.

Categorical and continuous variables were described as frequencies and median with interquartile ranges (IQR), respectively. The significance of the predictors was estimated using logistic regression. The ORR to capecitabine was considered the main effect maintained in the model. The interaction between ORR and capecitabine and other significant variables was evaluated. Subsequently, a stepwise selection process was performed at \( P = 0.10 \) for entering the model and \( P = 0.05 \) for remaining in the model; all parameters with \( P = 0.25 \) in the univariate analysis were considered. The Kaplan–Meier method was used to estimate PFS and OS. Survival curves were compared using the log-rank test and Cox regression analysis. A \( P \)-value <0.05 was considered statistically significant, and statistical analyses were performed using SPSS (version 27) (IBM Corp., Armonk, NY, USA).

### 3. Results

#### 3.1. Patients and Disease Characteristics

Fifty-one patients were eligible for this study, with a median age at diagnosis of 42 years (IQR: 35.5–52.5). The majority (98%) had non-keratinized undifferentiated squamous cell carcinoma and (97.2%) were Epstein–Barr virus-positive. In this cohort, 52.9% of patients had an initial presentation with localized disease and then developed recurrence; 47.1% presented with de novo metastases. Patient and disease characteristics are presented in Table 1. There was no prior use of fluoropyrimidine in this cohort. Capecitabine was used as the first-, second-, or third-line treatment in 21.6%, 35.3%, and 43.1% of the patients, respectively. Twenty-four patients received subsequent therapy after capecitabine treatment: gemcitabine [15], taxane [3], platinum [3], and immuno-therapy [3]. Data for response and tolerability to capecitabine were available for all patients, and eight patients were lost to follow-up (15.6%).

#### 3.2. Capecitabine ORR and Predictive Variables

ORR and DCR were 49% and 66.7%, respectively. The median duration of capecitabine treatment was 6.5 (IQR: 4.2–15.6) months, and the median duration of response was 6.2 (IQR: 3.3–13.5) months. Table 2 shows the best responses to capecitabine.

The patients with hand–foot syndrome (HFS) showed a higher ORR than those without (\( P = 0.02 \)). In addition, a history of smoking was associated with a lower ORR (\( P = 0.02 \)). However, data regarding smoking history were missing for 29.4% of the patients, and the active smoking status during therapy was unknown. There was no association between HFS and starting capecitabine with a lower dose vs. standard dose (\( P = 0.27 \)) or with the highest achieved capecitabine dose (standard vs. lower dose) (\( P = 0.91 \)). Table 3 presents the logistic regression analysis of the variables associated with the ORR to capecitabine in R/M NPC. The adjusted odds ratio for capecitabine dose showed that the development of HFS remained significant for the ORR (OR: 5.1 [95% CI: 1.18–21.98]; \( P = 0.02 \)).

#### 3.3. Survival Analysis

The median follow-up was 17.8 (IQR: 7.8–30.4) months. The median PFS was 6.6 (95% CI: 4.3–8.8) months, and the median OS was 32.7 (95% CI: 25.9–39.5) months; the order of using capecitabine (second-line vs. third-line) did not correlate with differences in PFS (\( P = 0.7 \)) or OS (\( P = 0.7 \)) (Figure 1).

The presence of HFS, ECOG-PS 0/1 vs. ≥2, and the absence of brain metastasis were associated with prolonged PFS (Figure 2(a)–2(c)). There were no significant differences in PFS with respect to sex (\( P = 0.33 \)), history of smoking (\( P = 0.45 \)), metastasis at diagnosis (\( P = 0.94 \)), recurrence type (\( P = 0.49 \)), bone metastasis (\( P = 0.70 \)), lung metastasis (\( P = 0.98 \)), liver metastasis (\( P = 0.97 \)), or type of chemotherapy (first-line anthracycline \( P = 0.48 \) or taxane \( P = 0.75 \)). In the multivariate Cox regression analysis, HFS (hazard ratio [HR]: 0.35 [95% CI: 0.14–0.87]; \( P = 0.02 \)), ECOG-PS (HR: 2.3 [95% CI: 1.10–4.87]; \( P = 0.02 \)), and brain metastasis (HR: 3.2 [95% CI: 1.04–10.07]; \( P = 0.04 \)) remained significant. There were trends for clinical differences in OS concerning HFS (median OS: 33.4 vs. 20.2 months) and absence of a history of smoking (median OS: 32.7 vs. 25.6 months). However, these differences were not statistically significant (\( P = 0.052 \) and \( P = 0.38 \), respectively).

#### 3.4. Capecitabine Tolerability

Twenty-one (41%) patients started with a standard dose of 1250 mg/m\(^2\), and 30 patients began the first cycle with a reduced dose of either 850 mg/m\(^2\) (10, 16%) or 1000 mg/m\(^2\) (20, 43%) and then escalated to the standard dose with good tolerance. Most patients (78.4%) tolerated the standard oral dose of 1,250 mg/m\(^2\) twice daily for 2 weeks, followed by a 1-week rest in 3-week cycles. Twenty percent of patients required a 25% dose reduction, and one required a 50% dose reduction. The reasons for capecitabine discontinuation were disease progression in 44

### Table 2: Best response to capecitabine.

| Response      | Number (%) |
|---------------|------------|
| Complete response | 8 (15.7)   |
| Partial response | 17 (33.3)  |
| Stable disease  | 9 (17.6)   |
| Progressive disease | 17 (33.3)  |
| ORR            | 25 (49)    |
| DCR            | 34 (66.7)  |

Abbreviations: DCR: disease control rate; ORR: objective response rate.
(86.2%) patients, patient request in three (5.8%) patients, and toxicity in three (5.8%) patients. After the first cycle, one patient developed fatigue, another developed neutropenia, and a third developed HFS, leading to treatment discontinuation; detailed toxicity profiles are shown in Table 4.

4. Discussion

This was the first study of capecitabine monotherapy in R/M NPC from the Middle East, specifically Saudi Arabia. The efficacy was comparable to the reported outcomes of
Figure 2: Continued.
previous studies that used capecitabine as a single-agent treatment for R/M NPC. The ORR of 49% and DCR of 66.7%, with a median response duration of 6.5 months, were comparable to or better than the corresponding values reported in previous studies (Table 5). The higher median OS of 32.7% (95% CI: 25.9–39.5) months in this
cohort in comparison to previous studies [25] cannot be attributed to capecitabine rather than to the patient and disease characteristics (e.g., median age of 42 years, ECOG-PS 0/1 >66.7%), and other subsequent chemotherapy treatment lines (47%).

The results were also comparable to those pertaining to immunotherapy [21–23]. Pembrolizumab had an ORR of 26% and a median duration of response of 17.1 months. The 1-year OS rate was 63%, the 1-year PFS rate was 34%, and approximately 30% of patients experienced a grade III–V drug-related adverse event [22]. Nivolumab had an ORR of 20%, a 1-year OS rate of approximately 59%, and a 1-year PFS rate of 19.3% in two-phase I/II trials [21, 23].

KEYNOTE-122 showed that, compared to chemotherapy, pembrolizumab did not improve the ORR, PFS, or OS of patients with recurrent metastatic NPC [27]. However, the addition of immune checkpoint inhibitors (toripalimab or camrelizumab) to gemcitabine plus cisplatin improved PFS in two separate phase III trials of R/M NPC [28, 29].

Most patients (80%) in our study tolerated the standard dose of capecitabine. Only 20% of patients required a 25% dose reduction, and one required a 50% dose reduction. Ten patients (19.6%) developed grade III or IV toxicities, and no hospitalizations or deaths due to toxicity were reported. A landmark East Asia study by Chau et al. of capecitabine use for NPC treatment reported that 41% of patients required hospitalization, and 11% died of treatment-related causes [20]. The incidence of toxicity in our patients was much lower than that reported in a previous study from China. This variation could be related to other factors, such as age at diagnosis, body weight, ECOG-PS, genetic polymorphisms associated with ethnicity, psychosocial factors, and dietary folate intake [30]. Recently, adjuvant therapy with capecitabine (650 mg/m²) after definitive chemoradiotherapy was shown to have high tolerability and a low toxicity profile in a Chinese study [31].

Our study confirmed that developing HFS is associated with a better objective response, as reported in a previous study. However, the incidence of HFS was lower in our patients (27.4% vs. 86%) [20]. HFS was first reported in 1984 with 5-fluorouracil [32], and later with cytarabine, doxorubicin, capecitabine, and other chemotherapeutic and biologic agents [33]. Development of HFS during capecitabine therapy has been associated with better outcomes in other cancers, e.g., colon [24], head and neck [19], and metastatic breast cancer [34]. Furthermore, a meta-analysis of more than 4,700 patients treated with capecitabine alone or in combination with other agents for solid cancers showed that patients who developed HFS had longer OS (36.1 vs. 22.7 months) (HR: 0.61 [95% CI: 0.56–0.66]) [35]. Serum folate (P < 0.001) and red blood cell folate (P = 0.001) levels were reported as predictors of grade II or higher HFS. HFS could be used as an encouraging prognostic variable of response to capecitabine therapy while treating patients with NPC.

Despite the limitation that smoking history data were missing for 29.4% of patients and active smoking status during therapy was unknown, we observed that the ORR was substantially higher among non-smokers, a finding that requires further research to validate the prognostic value of smoking.

We acknowledge the limitations of a retrospective study, which decreased the certainty of prognostic markers, such as smoking history, and the accuracy of non-hematological toxicity profiles and quality-of-life outcomes. Moreover, this study had a small sample size. However, the sample size was slightly larger than that reported in previous studies.

5. Conclusion

Capecitabine is an effective and well-tolerated chemotherapeutic agent conveniently used as a monotherapy for palliative treatment of R/M NPC. HFS was predictive of objective response and associated with better PFS. Further trials are required to obtain substantial evidence to support these findings.

Abbreviations

CI: Confidence interval
ECOG-PS: Eastern Cooperative Oncology Group Performance Status
HFS: Hand-foot syndrome
HR: Hazard ratio
IQR: Interquartile range
NPC: Nasopharyngeal carcinoma
OR: Odds ratio
ORR: Objective response rate
OS: Overall survival
PFS: Progression-free survival
R/M: Recurrent/metastatic

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This study was approved by the Research Advisory Council of King Faisal Specialist Hospital and Research Centre, Riyadh (RAC# 2191100). The requirement for informed patient consent was waived by the Research Approval Committee of the King Faisal Specialist Hospital and Research Centre, Riyadh. All methods were performed in accordance with the relevant guidelines and regulations.

Conflicts of Interest

The authors declare that there is no conflict of interest.

Authors’ Contributions

JA and BA conceived and designed the study. BA, JA, MK, and MA wrote the manuscript. BA designed the CRF, filtered the MRNs, and supervised data collection. BA, MK, AG, and MA collected the data. TE and BA analyzed the data. BA, AG, and TE created tables and wrote the first draft
of the manuscript. All authors critically revised the manuscript for important intellectual content and read and approved the final version of the manuscript.

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *Ca: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.

[2] “Global Cancer Observatory,” https://gco.iarc.fr.

[3] Saudi Health Council National Health Information Center, “Saudi Cancer Registry Cancer Incidence Report Saudi Arabia,” 2016, https://nhic.gov.sa/en/services/Pages/TumorRegistration.aspx.

[4] W. I. Wei and J. S. T. Sham, “Nasopharyngeal carcinoma,” *Lancet*, vol. 365, no. 9476, pp. 2041–2054, 2005.

[5] M. L. K. Chua, J. T. S. Wee, E. P. Hui, and A. T. C. Chan, “Nasopharyngeal carcinoma,” *Lancet*, vol. 387, no. 10022, pp. 1012–1024, 2016.

[6] J. J. Caudell, M. L. Gillison, E. Maghami et al., “NCCN Guidelines®: Insights: Head and Neck Cancers, Version 1.2022,” *Journal of the National Comprehensive Cancer Network*, vol. 20, no. 3, pp. 224–234, 2022.

[7] Y. Jin, X. Y. Cai, Y. X. Shi et al., “Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma,” *Journal of Cancer Research and Clinical Oncology*, vol. 138, no. 10, pp. 1717–1725, 2012.

[8] L. Zhang, Y. Huang, S. Hong et al., “Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial,” *Lancet*, vol. 388, no. 10054, pp. 1883–1892, 2016.

[9] Y. Bensouda, W. Kaikani, N. Abbeddou et al., “Treatment for metastatic nasopharyngeal carcinoma,” *European Annals of Ototorhinolaryngology, Head and Neck Diseases*, vol. 128, no. 2, pp. 79–85, 2011.

[10] D. T. Chua, D. L. Kwong, J. S. Sham, G. K. H. Au, and D. Choy, “A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy,” *European Journal of Cancer*, vol. 36, no. 6, pp. 736–741, 2000.

[11] R. K. C. Ngan, H. H. Y. Yiu, W. H. Lau et al., “Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study,” *Annals of Oncology*, vol. 13, no. 8, pp. 1252–1258, 2002.

[12] A. Prawira, S. F. Oosting, T. W. Chen et al., “Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review,” *British Journal of Cancer*, vol. 117, no. 12, pp. 1743–1752, 2017.

[13] F. Perri, G. Della Vittoria Scarpati, F. Caponigro et al., “Management of recurrent nasopharyngeal carcinoma: current perspectives,” *Oncotargets and Therapy*, vol. 12, pp. 1583–1591, 2019.

[14] P. J. Peng, X. Q. Ou, Z. B. Chen et al., “Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy,” *Cancer Chemotherapy and Pharmacology*, vol. 72, no. 2, pp. 323–328, 2013.

[15] K. F. Foo, E. H. Tan, S. S. Leong et al., “Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type,” *Annals of Oncology*, vol. 13, no. 1, pp. 150–156, 2002.

[16] E. Au, E. H. Tan, and P. T. Ang, “Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer,” *Annals of Oncology*, vol. 9, no. 3, pp. 327–329, 1998.

[17] D. Poon, B. Chowbay, Y. B. Cheung, S. S. Leong, and E. H. Tan, “Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma,” *Cancer*, vol. 103, no. 3, pp. 576–581, 2005.

[18] A. A. Forastiere, B. Metch, D. E. Schuller et al., “Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study,” *Journal of Clinical Oncology*, vol. 10, no. 8, pp. 1245–1251, 1992.

[19] D. T. T. Chua, J. S. T. Sham, and G. K. H. Au, “A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy,” *Oral Oncology*, vol. 39, no. 4, pp. 361–366, 2003.

[20] D. Chua, W. I. Wei, J. S. T. Sham, and G. K. H. Au, “Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer,” *Japanese Journal of Clinical Oncology*, vol. 38, no. 4, pp. 244–249, 2008.

[21] J. P. Delord, A. Hollebecque, J. P. De Boer et al., “An open-label, multicohort, phase II/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC),” *Journal of Clinical Oncology*, vol. 35, 15_Supplement, pp. 6025–6025, 2017.

[22] C. Hsu, S. H. Lee, S. Ejadi et al., “Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study,” *Journal of Clinical Oncology*, vol. 35, no. 36, pp. 4050–4056, 2017.

[23] B. B. Y. Ma, W. T. Lim, B. C. Goh et al., “Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742),” *Journal of Clinical Oncology*, vol. 36, no. 14, pp. 1412–1418, 2018.

[24] D. G. Haller, J. Cassidy, S. J. Clarke et al., “Potential regional differences for the tolerability profiles of fluoropyrimidines,” *Journal of Clinical Oncology*, vol. 26, no. 13, pp. 2118–2123, 2008.

[25] Y. M. Tian, W. Z. Huang, Y. H. Lan, C. Zhao, L. Bai, and F. Han, “Prognostic model and optimal treatment for patients with stage IVC nasopharyngeal carcinoma at diagnosis,” *Scientific Reports*, vol. 9, no. 1, pp. 1–7, 2019.

[26] E. Ciuleanu, A. Irimic, T. E. Ciuleanu, V. Popita, N. Todor, and N. Ghilezan, “Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study,” *Journal of BUON*, vol. 13, no. 1, pp. 37–42, 2008.

[27] A. T. Chan, V. H. F. Lee, R. L. Hong et al., “8580 Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC),” *Annals of Oncology*, vol. 32, p. S786, 2021.

[28] Y. Yang, S. Qu, J. Li et al., “Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind,
phase 3 trial,” *The Lancet Oncology*, vol. 22, no. 8, pp. 1162–1174, 2021.

[29] R. Xu, H. Q. Mai, Q. Y. Chen et al., ”JUPITER-02: randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC),” *Journal of Clinical Oncology*, vol. 39, 18_Supplement, p. LBA2, 2021.

[30] R. Midgley and D. J. Kerr, ”Capecitabine: have we got the dose right?,” *Nature Clinical Practice. Oncology*, vol. 6, no. 1, pp. 17–24, 2009.

[31] Y. P. Chen, X. Liu, Q. Zhou et al., ”Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial,” *Lancet*, vol. 398, no. 10297, pp. 303–313, 2021.

[32] J. J. Lokich and C. Moore, ”Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome,” *Annals of Internal Medicine*, vol. 101, no. 6, pp. 798-799, 1984.

[33] K. K. Miller, L. Gorcey, and B. N. McLellan, ”Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management,” *Journal of the American Academy of Dermatology*, vol. 71, no. 4, pp. 787–794, 2014.

[34] C. Twelves, W. Scheithauer, J. McKendrick et al., ”Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy,” *Annals of Oncology*, vol. 23, no. 5, pp. 1190–1197, 2012.

[35] C. Zielinski, I. Lang, S. Beslja et al., ”Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer,” *British Journal of Cancer*, vol. 114, no. 2, pp. 163–170, 2016.